The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
Read moreMinoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading E...
Read moreKala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported...
Read moreGalecto, Inc., a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline d...
Read moreNew innovations, like AELIX’ T-cell vaccine, leading to a prolonged period without ART, could be a gamechanger in HIV cure strategies as a combination approach to treating the disease.
Read moreClear path forward for ilofotase alfa as potential treatment in acute kidney injury, based on consistent improvement of renal parameters observed in REVIVAL and other clinical studies
Read moreXeltis, a medtech company developing the most advanced polymer-based restorative cardiovascular devices, today announced very promising preliminary efficacy and safety results from one of the centers ...
Read moreAura Biosciences today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Inv...
Read moreGalecto today announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis
Read moreSeagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors
Read moreSparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The rou...
Read moreEquity and licensing investment for aXess device marks first commercial deal
Read more